Two prescription pill bottles: Wegovy 1.5 mg (semaglutide) and Foundayo 0.8 mg (orforglipron) tablets.

Oral GLP-1 tablets

Trustpilot Phlo is rated excellent 4.8 out of 5

Sourced directly from manufacturers

UK-based clinical team providing check-ins

Access to Obesity Specialist Dietitian

Fully UK GPhC Registered Pharmacy, trusted by over 90,000 patients

Prices from

£89* / month

Get started

GLP-1 Tablets coming to the UK

Up to 16.6% weight loss
White bottle of Wegovy 1.5 mg (semaglutide) tablets, 30 count, prescription only.

Wegovy Tablet

GLP-1  |  Semaglutide
Wegovy tablets contain semaglutide and work by mimicking a natural hormone that signals to your brain when you're full, helping to reduce appetite and how much you eat.
Active ingredient:
Semaglutide (same as Wegovy injection)
Dosage form:
Once-daily oral tablet
Average weight loss in trials:
Up to ~14–17% of body weight
Starting dose:
1.5mg, titrating up to 25mg
Up to 12.4% weight loss
Bottle of Foundayo orforglipron 0.8 mg tablets by Lilly, containing 30 tablets.

Foundayo

GLP-1  |  Orforglipron
Foundayo (Orforglipron) is a next-generation oral GLP-1 medicine currently in late-stage clinical trials. Unlike semaglutide, it is a small molecule that does not require the same food and water restrictions when taken.
Dosage form:
Once-daily oral tablet
Average weight loss in trials:
Up to ~12.4% of body weight
UK availability:
Subject to regulatory review, expected late 2026.

What are oral GLP-1 tablets?

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of prescription-only medicines used to support weight management. Currently available in injectable form, following assessment by a clinician.

Oral GLP-1 tablets are being developed and studied as once-daily tablet formulations for weight management. These medicines work by mimicking the GLP-1 hormone, which can help regulate appetite and food intake.

Treatment suitability, availability and prescribing decisions are determined by a clinician following an appropriate consultation.

What are they?

Tablet-based weight loss treatments

Contain a GLP-1 receptor agonist (the same active ingredient as Wegovy)

Taken once daily, rather than once weekly by injection

Clinically tested with results comparable to injectable options

Why are people interested?

An option for people who would prefer not to inject

Convenient for those with busy or unpredictable routines

No need for refrigerated storage or injection supplies

The same clinically supported approach, in a familiar tablet format

How much weight can you lose on GLP-1 tablets?

What the evidence shows

Two large clinical trials give us the best picture so far. Here's what happened when real patients took oral GLP-1 tablets alongside diet and lifestyle support.

Wegovy tablet (oral semaglutide)

13.6%*

average body weight lost over 64 weeks

White bottle of Wegovy 1.5 mg (semaglutide) tablets, 30 count, prescription only.

In a study of 307 adults – that's roughly 1 in 4 losing 20% or more of their body weight.

Orforglipron

11.2%*

average body weight lost over 74 weeks

Bottle of Foundayo orforglipron 0.8 mg tablets by Lilly, containing 30 tablets.

In a study of 3,127 adults – over half lost at least 10% of their body weight.

How much weight lost Wegovy tablet1 Orforglipron2 Placebo
(no treatment)
At least 10% 60% 54.6% ~13%
At least 15% 47% 36% ~6%
At least 20% 28% 18.4% ~3%

* Averages from clinical trials in controlled settings alongside diet and lifestyle support. Individual results will vary.
* The two trials used different designs and durations and cannot be directly compared with each other.
* Both treatments are not yet available in the UK. Availability is subject to regulatory approval. Both expected in 2026.

Tablets vs injections: which is right for you?

Oral GLP-1 tablets and injectable GLP-1 treatments are both effective, clinically-proven options. The right choice depends on your personal preferences and circumstances. Here is a quick comparison:

Oral GLP-1 Tablets
Weekly Injections (Available Now)
Format Once-daily tablet Once-weekly injection (pen)
Availability Available now Available now
Clinically proven Yes Yes
Weight loss (avg) Up to ~17% Up to ~20%
Ongoing clinical support Yes – always included with Morrisons Clinic Yes – always included with Morrisons Clinic
Best for People who prefer not to inject People who want treatment now

* Averages from clinical trials in controlled settings alongside diet and lifestyle support. Individual results will vary.
* The two trials used different designs and durations and cannot be directly compared with each other.
* Both treatments are not yet available in the UK. Availability is subject to regulatory approval. Both expected in 2026.

Why choose Morrisons Clinic?

Clinician-led care: as with all Morrisons Clinic treatments, you will receive ongoing support from our UK-registered clinical team

No need to keep checking: we will do the monitoring and reach out when there is a meaningful update

Trusted by thousands of patients: Morrisons Clinic is powered by Phlo, a GPhC-regulated pharmacy

Expert guidance: our clinicians will help you understand whether oral GLP-1 treatment is right for you when it becomes available

Known side effects of GLP-1 tablets

Like all medicines, oral GLP-1 tablets can cause side effects. Most are digestive and tend to be mild to moderate, often settling down as your body adjusts during the first few weeks of treatment.

Common side effects

Wegovy Tablet (Semaglutide 25mg)
Foundayo (Orforglipron 17.2mg)

*This information is based on phase 3 clinical trial data and US prescribing information.
This is not a complete list of side effects. Always consult a qualified clinician before starting treatment.

Reviewed by
Dennis Ouko
|
2205052
|
Superintendent Pharmacist
Last reviewed:
20 May 2026